Abstract
The products of this market intelligence service will be provided in the
following volumes:
VOLUME 01: Global Overview and Company Profiles
VOLUME 02: National Markets
This new 2 volume, 714-page edition is packed with facts, figures, analysis
and statistics, that provides the most thorough analysis available on generic
markets, products and companies and the issues they face.
The changing face of the generics industry
Corporate consolidation continues to change the operating landscape, most
notably with the acquisition of Barr Pharma by Teva which has created by far
the largest generics company and a major player on the global pharmaceutical
stage. Big though the deal may be, it is just one of a number of events which
are seeing the rationalisation of the industry. In a separate and interesting
company development, Merck & Co has announced the development of a biosimilar
division in the US.
Is the credit crunch taking its toll?
For some generic players, tighter healthcare budgets may prove an opportunity
to boost sales. In contrast, those with high debt levels and restricted access
to credit may struggle to survive in their current form.
Key company, market and product information
To understand the generic market, Espicom, the publisher of the respected
twice-monthly business publication World Generic Markets, has published The
World Generic Market Report 2009. Packed with facts, figures, analysis and
statistics, the new 2 volume 714-page edition provides the most thorough
analysis available on generic markets, products and companies and the issues
they face.
Industry consolidation, company survival, new market opportunities, the latest on biosimilars plus much more!
Published in January 2009, this report draws on primary research with
companies, statistics offices, health ministries and trade associations
worldwide and provides standard, comparative data and discussion on key issues
such as:
- Industry consolidation and the emergence of “super” generic
companies
- Generic market growth - but where?
- Biosimilars: continued development in Europe but no action in US - will
the new Obama government break the deadlock?
- Are changes afoot in EU generic regulation
- Key legal challenges
- The political and funding background
- Intellectual property issues
Understand the corporate threats and market opportunities that are shaping
this rapidly evolving sector.
| 
View Cart
